On April 8, 2016, a Judge in the Southern District of Florida granted Plaintiffs’ Motion for Preliminary Approval of a $14.75M class action settlement of a suit against Shire Pharmaceuticals. The settlement covers a class of persons from 35 states and the District of Columbia who bought attention deficit hyperactivity disorder drug Adderall XR since January 2007 and includes the settlement of suits filed in Pennsylvania, New Jersey and Massachusetts.
These pay-for-delay suits alleged Shire paid generic-drug makers to delay selling cheaper versions of the drug, and used other anti-competitive tactics in violation antitrust laws and state consumer protection laws causing millions of dollars in damages to consumers who were required to pay higher prices for brand Adderall XR pending generic availability.
Pursuant to the Judge’s ruling, Plaintiffs will submit a Motion for Final Approval of the Settlement by September 16, 2016 and the Fairness hearing will be on November 9, 2016. For the full ruling, click here.